From PK to IND: How Integrated PK/PD, Bioanalysis, and Infectious Disease Expertise Accelerate Development
As infectious disease programs advance toward IND, fragmentation becomes a major risk. PK studies may be performed by one vendor, bioanalysis by another, disease models by a third, and toxicology by yet another. Each handoff introduces variability, communication gaps, and opportunities for misalignment.
An effective IND-enabling strategy requires integration—scientific, operational, and regulatory.
Bioanalysis as the Backbone of PK/PD Programs
Bioanalytical and biomarker strategies often operate behind the scenes, yet they underpin PK/PD interpretation. Depending on the compound and mechanism, sponsors may require mass spectrometry, gas chromatography, ELISA, ELISpot, hematology, immune profiling, or tissue distribution analysis.
The choice of bioanalytical method depends entirely on what the sponsor is trying to measure. Blood levels, tissue penetration, enzymatic effects, immune responses—all require different tools. As programs advance, assays that support key regulated decisions should be appropriately qualified or validated for their intended use, with GLP compliance applied where required. Failing to align bioanalytical strategy early often results in rework just as programs enter pivotal stages, when timelines are tightest and flexibility is lowest.
Dose Range Finding and Study Design Efficiency
PK/PD data directly inform dose range finding studies, which are essential for defining therapeutic and toxic exposure boundaries. In some early studies, the use of crossover approaches, where multiple dose conditions may be administered to the same animals, washout is adequate and carryover effects are unlikely.
When scientifically appropriate, this approach can reduce inter-animal variability, support reduction and refinement under the 3Rs, and generate useful comparative data. From these studies, sponsors can identify doses that appear therapeutic, doses that trend toward toxicity, and the dosage spacing needed for GLP toxicology studies.
In dose-range finding and toxicology planning, adequately separated dose levels are often important to define exposure-response relationships and safety margins, although practical constraints may limit spacing. When that is not possible due to solubility or formulation constraints, early discussions with the FDA become critical to align expectations.
Modeling, Simulation, and Regulatory Alignment
PK/PD modeling and simulation further strengthen IND packages. Predictive modeling can help sponsors explore how structural changes to a compound may affect absorption, clearance, or tissue distribution. These tools can reduce unnecessary animal use, guide study design, and help interpret experimental results.
Modeling can be used both prospectively and retrospectively predicting outcomes and then validating those predictions with in vivo data. When aligned with experimental results, modeling provides a powerful narrative that regulators increasingly expect to see.
Why End-to-End Capability Matters
What ultimately differentiates Southern Research is the ability to conduct PK/PD studies, infectious disease efficacy studies, dose range finding, toxicology, and bioanalysis within a single, integrated organization.
Often, there is a common scenario sponsors encounter when work is fragmented: studies that appear successful on paper but cannot be replicated or advanced because formulation, disease modeling, or bioanalysis were not aligned. When everything is conducted in-house, scientific continuity is preserved, and problems are identified early—before they become costly failures.
For emerging biotech companies, this integrated approach translates into fewer delays, clearer dose justification and study progression planning, and a development partner that understands infectious disease drug development from molecule to IND.